본문 바로가기

Impact of diabetes mellitus and hypertension on renal function during first-line targeted therapy for metastatic renal cell carcinoma: a retrospective multicenter study

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q2
저널
TRANSLATIONAL ANDROLOGY AND UROLOGY13(9) · pp.1912 · 2024
피인용
Web of Science 2Scopus 0
FWCI (Scopus)
0
JCR IF
JCR 2023 1.9
ISSN
2223-4683

저자

  1. Gu, Hui Mo제1저자Chonnam Natl Univ, Hwasun Hosp, Dept Urol, Med Sch, Hwasun, South Korea
  2. Sou, Sung JunInje Univ, Busan Paik Hosp, Coll Med, Dept Urol, 75 Bokji Ro, Pusan 47392, South Korea
  3. Ku, Ja YoonDongnam Inst Radiol & Med Sci, Dept Urol, Canc Ctr, Pusan, South Korea
  4. 김경환Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Urol, Pusan, South Korea
  5. 박영주Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Internal Med, Pusan, South Korea
  6. Choi, Seock HwanKyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Urol, Daegu, South Korea
  7. 하홍구Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Urol, Pusan, South Korea
  8. Hwang, Eu ChangChonnam Natl Univ, Hwasun Hosp, Dept Urol, Med Sch, Hwasun, South Korea
  9. 이찬호교신저자Inje Univ, Busan Paik Hosp, Coll Med, Dept Urol, 75 Bokji Ro, Pusan 47392, South Korea

초록

Background: Renal function deterioration during systemic therapy in patients with metastatic renal cell carcinoma (mRCC) is a long-term concern in treatment planning. Although hypertension (HTN) and diabetes mellitus (DM) are the most common factors that affect chronic kidney disease (CKD) development and progression, their impact on renal function during targeted therapy is unclear. This study investigated whether DM and HTN were associated with a decline in renal function during first-line targeted therapy for mRCC. Methods: This retrospective multicenter study analyzed patients receiving first-line targeted therapy for mRCC. They were classified as follows: group 1: HTN−, DM−; group 2: HTN+, DM−; group 3: HTN−, DM+; and group 4: HTN+, DM+. Changes in renal function and factors affecting progression to stage 4 CKD after targeted therapy were analyzed. Results: Among the 424 enrolled patients, 303 (71.5%) and 121 (28.5%) were treated with sunitinib and pazopanib, respectively [median duration: 10.3 months, interquartile range (IQR), 3.1–37.0 months]. Although all groups showed a decreased mean estimated glomerular filtration rate (eGFR) after treatment (P<0.001 for group 1, group 2, and group 4, P=0.02 for group 3, respectively), there were no significant differences in changes in eGFR (∆eGFR) between groups (P=0.10). However, actual renal function change calculated using percent ∆eGFR (%∆eGFR) showed differences between groups (P=0.02); the %∆eGFR of group 4 was significantly lower compared with group 1 (P=0.008). The mean progression time to stage 4 CKD in group 4 (38.6 months) was significantly shorter compared to the other groups (P<0.001). Multivariate analysis identified increased age (P=0.008), increased number of metastatic sites (P=0.047), and DM and HTN coexistence (P<0.001) as predictors of progression to stage 4 CKD. Conclusions: Patients with DM and HTN experienced further decline in renal function and had a higher risk of progression to stage 4 CKD after targeted therapy compared to patients without these risk factors. Recognition and proactive management of DM and HTN are necessary to facilitate the proper administration of life-prolonging oncological treatments.

키워드

chronic kidney disease (CKD)diabetes mellitus (DM)hypertension (HTN)renal functionTargeted therapyKIDNEY-FUNCTIONNEPHROPATHYMANAGEMENTGUIDELINESUNITINIBDISEASERISKVEGF

식별자

Scopus EID
2-s2.0-85205442831
WoS UID
001359769600017